Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

McLean Hospital and Repligen announce results of brain imaging study of secretin

01.11.2002


Secretin is active in a brain region implicated in autism



Researchers from the Brain Imaging Center at McLean Hospital and Repligen Corporation (Nasdaq: RGEN) reported today the results of a clinical trial designed to assess the neurological activity of secretin by functional magnetic resonance imaging (fMRI). The results demonstrate for the first time in humans, that secretin is active in the central nervous system and that it potentiates activity in the amygdala, a region of the brain involved in social integration and implicated in autism. The findings were presented today by Deborah Yurgelun-Todd, Ph.D., of McLean Hospital, the study’s Principal Investigator, at the International Meeting for Autism Research, a satellite meeting of the Society for Neuroscience.

"Our results demonstrate for the first time that secretin is a neuroactive peptide in humans and that it acts on a brain region known to be important for social interaction," stated Yurgelun-Todd, Director of Cognitive Neuroimaging at the Brain Imaging Center at McLean Hospital. "These findings suggest that secretin may have a role in modulating certain social behavior in humans."


The study was a double-blind, placebo-controlled clinical trial in 12 healthy men. Each subject was presented with a series of pictures of faces with either a neutral, happy or fearful facial expression to establish a baseline response. Following an injection of either secretin or a placebo, the subjects were again presented with the series of facial expressions. Throughout the experiment, the activation of the amygdala was recorded with MRI. There was a significant activation (p=0.001) of the right amygdala by secretin when the subjects viewed pictures of a fearful face compared to both the placebo group and the baseline response to the pictures in the secretin group. By contrast, there was no difference in amygdala activation when subjects viewed pictures of neutral or happy faces. Failure to activate the amygdala when viewing fearful faces is a characteristic of people with autism and patients with amygdala damage. The current study was initiated as part of ongoing research efforts to understand secretin as a neurologically active peptide. Repligen previously reported a finding that treatment of rats with secretin specifically activates the neurons in the amygdala. Repligen is currently developing secretin for autism in a Phase 3 clinical trial program.

"These studies show that secretin is active in a part of the human brain involved in social interaction and potentiates its activity during a social task known to be difficult for people with autism," stated Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen Corporation. "These data provides a plausible biological mechanism for the improvements in social interaction we observed in our Phase 2 clinical trial."

The Amygdala and the Social Deficits of Autism

The amygdala is part of a complex neural system that is critical for ascribing emotional value to stimuli and influencing affective responsiveness and emotional learning. One of the core deficits of autism is impaired reciprocal social interaction, including eye contact, joint attention and an inability to deduce the mental states of others from facial expressions. Reduced activation of the amygdala in patients with autism has been documented using fMRI with specific impairment noted in their ability to respond to facial expressions of fear. Other studies indicate that patients with either surgical or congenital amygdala damage show similar face recognition defects. Lack of activation of the amygdala is recognized as an important correlate of the social deficits of autism.

Repligen’s President and CEO Walter C. Herlihy, Ph.D. also presented data from its Phase 2 clinical trial. The Phase 2 study evaluated three administrations of secretin or a placebo in 126 patients aged 3 years to 6 years 11 months with moderate to severe symptoms of autism and gastrointestinal disorders. The primary finding of the Phase 2 clinical trial was that younger children, 3 and 4 year olds, showed improvements in reciprocal social interaction as judged by a standardized clinical instrument for the assessment of autistic symptoms. Repligen is currently conducting a Phase 3 clinical trial of secretin for the improvement of reciprocal social interaction in young children with autism.


About McLean Hospital
McLean Hospital maintains the largest research program of any private, U.S. psychiatric hospital. It is the largest psychiatric teaching facility of Harvard Medical School, an affiliate of Massachusetts General Hospital and a member of Partners HealthCare. The Brain Imaging Center at McLean is one of the largest imaging centers in the world, actively engaged in clinical research studies of brain function. Researchers at McLean were part of the team that first identified regional abnormalities in brain activation in patients with schizophrenia and in normal aging, as well as regional changes in blood flow and metabolism in patients with Alzheimer’s disease.

About Repligen Corporation
Repligen Corporation is a biopharmaceutical company committed to being the leader in the development of new drugs for pediatric developmental disorders including autism, immune and metabolic disorders. Repligen has a specialty pharmaceuticals business comprised of rProtein ATM and SecreFloTM, the profits from which will be used to support the development of our proprietary products. rProtein ATM is a consumable reagent used by the pharmaceutical industry to produce a class of drugs called monoclonal antibodies and SecreFloTM, secretin for injection, is marketed to gastroenterologists for pancreatic assessment. Repligen’s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

Renee L. Connolly | EurekAlert!

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>